Skip to main content

Decheng Capital — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

51
Companies
$3.8B
Total invested
$77.1M
Avg. check
13
Industries
Biotechnology 17Health Care 15Medical 8Biopharma 7Pharmaceutical 5Medical Device 4+7 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 51
Equillium
March 2026

Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.

Biopharma · La Jolla$35.0M Post Ipo Equity
Polares Medical
March 2026

Polares medical is a medical device company with a novel device for treating mitral valve regurgitation.

Health Care · Palo Alto$50.0M Series C
Phrontline Biopharma
November 2025

Phrontline Biopharma develops biopharmaceutical products to treat cancer through innovative antibody-drug conjugate technology.

Biopharma · Shanghai$60.0M Seed
Kind Pharmaceutical
November 2025

Kind Pharmaceutical is a clinical-stage biopharmaceutical company that focuses on the discovery and development of anemia drugs.

Biopharma · Hangzhou$56.2M Series C
Excellergy
October 2025

Excellergy develops portfolio of trifunctional effector cell response inhibitors (ECRIs) to combat severe allergic diseases.

Biotechnology · Palo Alto$70.0M Series A
Nalu Medical
September 2025

Nalu Medical is a medical technology company that offers neurostimulation system designed to treat chronic nerve pain.

Health Care · Carlsbad$50.0M Series Unknown
YolTech Therapeutics
September 2025

Yaotang Bio is a biotechnology company focusing on combining LNP delivery and gene editing technology.

Biopharma · Minhang$42.1M Series B
Haoxinqing
February 2025

Haoxinqing is an online medical service platform focusing on the fields of mental psychology and chronic disease management.

Health Care · BeijingSeries D
Medtech Technology
September 2024

Medtech Technology is a firm that develops innovative ophthalmic medical devices.

Health Care · Qiantang$28.2M Series B
LevitasBio
March 2024

LevitasBio is advancing science and human health by providing researchers with a new and powerful method of cellular analysis.

Analytics · San Francisco$11.8M Series Unknown
ImmPACT Bio
February 2024

ImmPACT Bio USA is developing novel cell therapies for treating cancer.

Biotechnology · Camarillo$8.0M Grant
Firefly Bio
February 2024

Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.

Biotechnology · San Francisco$94.0M Series A
PackGene Biotech
December 2023

PackGene Biotech provides CRO/CDMO services for gene therapy and cell therapy researchers and developers.

Biotechnology · Houston$14.1M Series C
KeChow Pharma
November 2023

KeChow Pharma, Inc. is a biopharmaceutical company focused on novel drug discovery.

Biopharma · PudongSeries Unknown
LYNK Pharmaceuticals
September 2023

LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines.

Biotechnology · Hangzhou$16.7M Series C
VintaBio
April 2023

VintaBio is a life sciences company that offers cell and gene therapy manufacturing services.

Biotechnology · Philadelphia$64.0M Series Unknown
Apexigen
January 2023

Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new antibody therapeutics for oncology.

Biopharma · San Carlos$2.8M Post Ipo Equity
Xtremity
October 2022

Xtremity develops a medical device to offer better connection sockets for prosthetics.

Health Care · Denver$8.1M Series B
ACELYRIN
September 2022

ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies.

Biopharma · Los Angeles$300.0M Series C
Watchmaker Genomics
June 2022

Watchmaker Genomics is a biotechnology company that focuses on breakthrough applications for reading, writing, and editing DNA.

Biotechnology · Boulder$40.0M Series A
USCI Medical Laboratory
May 2022

USCI Medical Laboratory is a national high-tech company that offers genetic testing services.

Health Care · HaidianPrivate Equity
AnHeart Therapeutics
December 2021

AnHeart Therapeutics is a developer of innovative pharmaceutical products.

Biotechnology · Hangzhou$61.0M Series B
Shape Therapeutics
July 2021

A biotechnology company developing RNA technologies to shape the future of gene therapy

Biotechnology · Seattle$112.0M Series B
Hummingbird Bioscience
May 2021

Hummingbird Bioscience focuses on the discovery and early development of oncology drugs.

Biotechnology · Woodlands$125.0M Series C

Where Decheng Capital invests

Biotechnology17
Health Care15
Medical8
Biopharma7
Pharmaceutical5
Medical Device4

About Decheng Capital's portfolio

How many companies has Decheng Capital invested in?

Decheng Capital has invested in 51 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Decheng Capital invest in?

Decheng Capital's top investment sectors include Biotechnology, Health Care, Medical, Biopharma, Pharmaceutical. The firm invests across 13 different industry categories.

What is Decheng Capital's largest investment?

Among tracked funding rounds, ACELYRIN received $300.0M in a Series C round. Decheng Capital's total known invested capital is $3.8B.

What is the average investment size for Decheng Capital?

Decheng Capital's average investment size is $77.1M across its portfolio of 51 companies.

What are Decheng Capital's most recent investments?

Recent Decheng Capital portfolio additions include Equillium, Polares Medical, Phrontline Biopharma, Kind Pharmaceutical, Excellergy. These companies were founded in 2020 or later.

Reach the founders behind these 51 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →